Skip to main content
Log in

Surveillance of Genetic Engineering: Will Restraints continue to Loosen?

  • Feature
  • Published:
Bio/Technology Submit manuscript

Government oversight of genetic engineering in the U.S. is on the verge of shifting its concerns from safety in experimentation to areas such as gene therapy and other uses that affect humans directly. To the relief of industrial observers, this oversight will probably focus on clinical applications rather than the manufacturing of substances. Few similiar signs are apparent elsewhere, but other countries are keeping an eye on U.S. developments. Around the world, the trend toward relaxation of regulation continues.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Powledge, T. Surveillance of Genetic Engineering: Will Restraints continue to Loosen?. Nat Biotechnol 1, 322–328 (1983). https://doi.org/10.1038/nbt0683-322

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0683-322

  • Springer Nature America, Inc.

This article is cited by

Navigation